Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

Health Economics Review

Table 6 Deterministic Sensitivity Analysis (ICERs of assessed antipsychotics versus haloperidol)

Parameter	Incremental Cost (€)	Incremental QALYs	ICER versus haloperidol (€/QALY gained)
Base case (BC)
Amisulpride	925	0.0101	91,584
Aripiprazole	1,390	0.0147	94,558
Olanzapine	574	0.0243	23,621
Paliperidone ER	-260	0.0341	Dominant
Risperidone	-128	0.0105	Dominant
Probability of relapse +20% BC
Amisulpride	795	0.0099	80,303
Aripiprazole	1,227	0.0144	85,208
Olanzapine	317	0.0258	12,287
Paliperidone ER	-632	0.0373	Dominant
Risperidone	-279	0.0107	Dominant
Probability of relapse -20% BC
Amisulpride	986	0.0150	65,733
Aripiprazole	1,495	0.0131	114,122
Olanzapine	773	0.0238	32,479
Paliperidone ER	55	0.0326	1,687
Risperidone	-35	0.0099	Dominant
Probability of discontinuation due to AE +20% BC
Amisulpride	861	0.0097	88,763
Aripiprazole	1,356	0.0130	104,308
Olanzapine	516	0.0238	21,681
Paliperidone ER	-287	0.0319	Dominant
Risperidone	-184	0.0099	Dominant
Probability of discontinuation due to AE -20% BC
Amisulpride	930	0.0104	89,423
Aripiprazole	1,373	0.0163	84,233
Olanzapine	575	0.0249	23,092
Paliperidone ER	-291	0.0362	Dominant
Risperidone	-141	0.0114	Dominant
Probability of discontinuation due to other reasons +20% BC
Amisulpride	868	0.0094	92,340
Aripiprazole	1,358	0.0135	100,593
Olanzapine	490	0.0243	20,165
Paliperidone ER	-364	0.0349	Dominant
Risperidone	-211	0.0100	Dominant
Probability of discontinuation due to other reasons -20% BC
Amisulpride	923	0.0105	87,905
Aripiprazole	1,363	0.0157	86,815
Olanzapine	601	0.0242	24,835
Paliperidone ER	-213	0.0332	Dominant
Risperidone	-103	0.0106	Dominant

ISSN: 2191-1991